KALVISTA PHARMACEUTICALS, INC.
One Kendall Square,
Bld 200, Ste 2203
Cambridge, MA 02139
April 26, 2017
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
| Attention: | Suzanne Hayes |
Assistant Director
Office of Healthcare and Insurance
| Re: | KalVista Pharmaceuticals, Inc. |
Registration Statement on Form S-3
Filed March 29, 2017, as amended
File No. 333-217009
Via EDGAR—Acceleration Request
| Requested Date: | April 28, 2017 |
| Requested Time: | 4:00 p.m. Eastern Time |
Ladies and Gentlemen:
KalVista Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Robert A. Freedman or Effie Toshav, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
| Sincerely, | ||
| KALVISTA PHARMACEUTICALS, INC. | ||
| By: |
/s/ Benjamin L. Palleiko | |
| Benjamin L. Palleiko | ||
| Chief Financial Officer | ||
| cc: | Thomas Andrew Crockett, Chief Executive Officer |
| KalVista Pharmaceuticals, Inc. |
| Robert A. Freedman, Esq. |
| Effie Toshav, Esq. |
| Fenwick & West LLP |